دورية أكاديمية
LC-MS/MS method for the quantitation of decitabine and venetoclax in rat plasma after SPE: Application to pharmacokinetic study.
العنوان: | LC-MS/MS method for the quantitation of decitabine and venetoclax in rat plasma after SPE: Application to pharmacokinetic study. |
---|---|
المؤلفون: | Alnasser AI; Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia., Hefnawy MM; Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia., Al-Hossaini AM; Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia., Bin Jardan YA; Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia., El-Azab AS; Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia., Abdel-Aziz AM; Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia., Al-Obaid AM; Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia., Al-Suwaidan IA; Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia., Attwa MW; Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia., El-Gendy MA; Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia. |
المصدر: | Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society [Saudi Pharm J] 2023 Sep; Vol. 31 (9), pp. 101693. Date of Electronic Publication: 2023 Jul 04. |
نوع المنشور: | Journal Article |
اللغة: | English |
بيانات الدورية: | Publisher: Saudi Pharmaceutical Society Country of Publication: Saudi Arabia NLM ID: 9705695 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1319-0164 (Print) Linking ISSN: 13190164 NLM ISO Abbreviation: Saudi Pharm J Subsets: PubMed not MEDLINE |
أسماء مطبوعة: | Publication: Riyadh : Saudi Pharmaceutical Society Original Publication: Riyadh, Kingdom of Saudi Arabia : The Society, |
مستخلص: | This study developed a novel, sensitive and selective LC-MS/MS method for the concurrent determination of DCB and VTX in rat plasma using encorafenib as internal standard (IS). To identify DCB, VTX, and IS, the positive multiple reaction monitoring (MRM) mode was used. Chromatographic separation was carried out using a reversed-phase Agilent Eclipse plus C18 column (100 mm × 2.1 mm, 3.5 µm) and an isocratic mobile phase made up of water with 0.1% formic acid and acetonitrile (50:50, v/v, pH 3.2) at a flow rate of 0.30 mL/min for 3.0 min. Prior to analysis, the DCB and VTX with the IS were extracted from plasma using the solid-phase extraction (SPE) method. High recovery rates for DCB, VTX and IS were achieved using the C18 cartridge without interference from plasma endogenous. The developed method was validated as per the FDA guidelines over a linear concentration range in rat plasma from 5-3000 and 5-1000 ng/mL for DCB and VTX, respectively with r 2 ≥ 0.998. For both drugs, the lower limits of detection (LLOD) were 2.0 ng/mL. After the HLOQ sample was injected, less than 20% of the LLOQ of DCB, VTX, and less than 5% of the IS carry-over in the blank sample was attained. The overall recoveries of DCB and VTX from rat plasma were in the range of 90.68-97.56%, and the mean RSD of accuracy and precision results was ≤6.84%. For the first time, the newly developed approach was effectively used in a pharmacokinetic study on the simultaneous oral administration of DCB and VTX in rats that received 15.0 mg/kg of DCB and 100.0 mg/kg of VTX. Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (© 2023 The Author(s).) |
References: | Cancer Sci. 2021 Sep;112(9):3636-3644. (PMID: 34185931) Blood Adv. 2020 Jul 14;4(13):2866-2870. (PMID: 32589727) Comput Methods Programs Biomed. 2010 Sep;99(3):306-14. (PMID: 20176408) Cancer. 1989 Mar 15;63(6):1055-9. (PMID: 2917307) J Chromatogr B Analyt Technol Biomed Life Sci. 2013 Feb 15;917-918:78-83. (PMID: 23369881) Leuk Lymphoma. 2020 Nov;61(11):2700-2707. (PMID: 32543932) Br J Haematol. 2020 Mar;188(6):918-923. (PMID: 31682002) Bioanalysis. 2022 Jan;14(2):75-86. (PMID: 34841894) J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Jun 15;899:81-5. (PMID: 22626892) Ulster Med J. 2007 Sep;76(3):131-5. (PMID: 17853637) Blood. 2023 Jan 26;141(4):345-355. (PMID: 35926108) Cancer Discov. 2016 Oct;6(10):1106-1117. (PMID: 27520294) Rapid Commun Mass Spectrom. 2006;20(7):1117-26. (PMID: 16523529) Ann Hematol. 2020 Apr;99(4):693-701. (PMID: 32025842) Drugs. 2016 Jun;76(9):979-87. (PMID: 27260335) Drugs Context. 2019 Oct 09;8:212574. (PMID: 31645879) Molecules. 2022 Feb 28;27(5):. (PMID: 35268708) Blood. 2019 Jan 3;133(1):7-17. (PMID: 30361262) N Engl J Med. 2015 Sep 17;373(12):1136-52. (PMID: 26376137) Biomedicines. 2023 Feb 20;11(2):. (PMID: 36831175) J Pharm Biomed Anal. 2021 Jul 15;201:114108. (PMID: 33962179) |
فهرسة مساهمة: | Keywords: Acute myeloid leukemia; Decitabine; LC–MS/MS; Pharmacokinetics; Rat plasma; Venetoclax |
تواريخ الأحداث: | Date Created: 20230810 Latest Revision: 20230811 |
رمز التحديث: | 20230811 |
مُعرف محوري في PubMed: | PMC10407895 |
DOI: | 10.1016/j.jsps.2023.06.026 |
PMID: | 37559870 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1319-0164 |
---|---|
DOI: | 10.1016/j.jsps.2023.06.026 |